EEA Life Settlements Fund PCC Limited
Update regarding Implementation Date for 2024 Reconstruction

Further to the EGM of EEA Life Settlements Fund PCC Limited (the Company) on Wednesday 24 January 2024, following separate Class Meetings of its shareholders, at which all resolutions put to shareholders at each meeting respectively were passed, the Implementation Date for the 2024 Reconstruction has now been fixed by the Board for 1 March 2024. Definitions used within the shareholder circular dated 13 December 2023 will apply to terms in this notice.

On the Implementation Date, each Shareholder will receive the number of New Run-off Shares and/or New Continuing Shares as is proportionate to their share of the Net Asset Value of the Company (less any costs and expenses associated with the Proposals) by reference to a NAV per New Cell Share of GBP1.00 on the Implementation Date.

Shareholders are expected to be notified of their holdings of New Cell Shares no later than 15 Business Days following the Implementation Date. Given that the conversion of Shares into New Cell Shares will be made by reference to the Net Asset Value at 29 February 2024 and, accordingly, there will be a short delay on all valuation data becoming available to the Company, Shareholders are kindly asked to wait for such revised holdings to be notified to them and contract notes detailing such revised holdings will be sent to Shareholders in the usual format and manner. As a result of the conversion process, transfers will be suspended for the calendar month of March.

Shareholders should note that irrespective of the currency of the Shares they currently hold, the New Cell Shares will be denominated in GBP and any future payments made by the Company to Shareholders following the Implementation Date will be denominated in GBP.

No cash payment shall be made or returned in respect of any fractional entitlements. All of the existing Cells will cease to exist following the Implementation Date, leaving only the New Run-off Cell and the New Continuing Cell.